Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

* Histologically confirmed advanced solid tumor for which no standard or effective treatment is available

  * Patients who refuse an available standard but non-curative treatment may also be eligible
* Tumors must produce CEA as documented by either an elevated serum CEA above the upper limit of normal (ULN) or by immunohistochemical (IHC) methods

  * Positive CEA IHC stain is determined if more than 30% of the tumor cells have an intensity of 2+ or greater
* Measurable disease
* Estimated \< 1/3 of liver involvement if tumor involves the liver
* No brain or leptomeningeal involvement with cancer

PATIENT CHARACTERISTICS:

* Karnofsky performance status 60-100%
* Life expectancy ≥ 3 months
* WBC ≥ 4,000/μL
* ANC ≥ 1,500/μL
* Platelet count ≥ 125,000/μL
* Creatinine ≤ 1.5 mg/dL and/or creatinine clearance \> 60 mL/min
* Bilirubin ≤ 1.5 mg/dL
* ALT and AST ≤ 2 times ULN
* Negative pregnancy test
* Fertile patients must use effective contraception
* Patients currently being treated for severe infections or recovering from other intercurrent illnesses (such as poorly controlled diabetes or hypertension) are ineligible until recovery is deemed complete by the investigator
* Serum anti-antibody testing must be negative for human anti-humanized antibodies (if patient received prior monoclonal antibody)
* Serum HIV-negative
* Serum hepatitis B antigen- and hepatitis C antibody-negative

PRIOR CONCURRENT THERAPY:

* At least 4 weeks since prior radiotherapy, immunotherapy, or chemotherapy (6 weeks for mitomycin C or nitrosoureas) and recovered
* Recovered from prior major surgery
* No prior radiotherapy to \> 50% of bone marrow
* No other concurrent chemotherapy, radiotherapy, or immunotherapy